Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome

S. Ruiz-Pinto, G. Pita, A. Patiño-García, P. García-Miguel, J. Alonso, A. Pérez-Martínez, A. Sastre, G. Gómez-Mariano, A. Lissat, K. Scotlandi, M. Serra, R. Ladenstein, E. Lapouble, G. Pierron, U. Kontny, P. Picci, H. Kovar, O. Delattre, Anna González-Neira

Research output: Contribution to journalArticlepeer-review


Background: Despite the effectiveness of current treatment protocols for Ewing sarcoma (ES), many patients still experience relapse, and survival following recurrence is <15%. We aimed to identify genetic variants that predict treatment outcome in children diagnosed with ES. Patients and methods: We carried out a pharmacogenetic study of 384 single-nucleotide polymorphisms (SNPs) in 24 key transport or metabolism genes relevant to drugs used to treat in pediatric patients (<30 years) with histologically confirmed ES. We studied the association of genotypes with tumor response and overall survival (OS) in a discovery cohort of 106 Spanish children, with replication in a second cohort of 389 pediatric patients from across Europe. Results: We identified associations with OS (P < 0.05) for three SNPs in the Spanish cohort that were replicated in the European cohort. The strongest association observed was with rs7190447, located in the ATP-binding cassette subfamily C member 6 (ABCC6) gene [discovery: hazard ratio (HR) = 14.30, 95% confidence interval (CI) = 1.53-134, P = 0.020; replication: HR = 9.28, 95% CI = 2.20-39.2, P = 0.0024] and its correlated SNP rs7192303, which was predicted to have a plausible regulatory function. We also replicated associations with rs4148737 in the ATP-binding cassette subfamily B member 1 (ABCB1) gene (discovery: HR = 2.96, 95% CI = 1.08-8.10, P = 0.034; replication: HR = 1.60, 95% CI = 1.05-2.44, P = 0.029), which we have previously found to be associated with poorer OS in pediatric osteosarcoma patients, and rs11188147 in cytochrome P450 family 2 subfamily C member 8 gene (CYP2C8) (discovery: HR = 2.49, 95% CI = 1.06-5.87, P = 0.037; replication: HR = 1.77, 95% CI = 1.06-2.96, P = 0.030), an enzyme involved in the oxidative metabolism of the ES chemotherapeutic agents cyclophosphamide and ifosfamide. None of the associations with tumor response were replicated. Conclusion: Using an integrated pathway-based approach, we identified polymorphisms in ABCC6, ABCB1 and CYP2C8 associated with OS. These associations were replicated in a large independent cohort, highlighting the importance of pharmacokinetic genes as prognostic markers in ES.

Original languageEnglish
Article numbermdw234
Pages (from-to)1788-1793
Number of pages6
JournalAnnals of Oncology
Issue number9
Publication statusPublished - Sep 1 2016


  • Ewing sarcoma
  • Pathway-based approach
  • Pharmacokinetic genes
  • Polymorphisms
  • Prognostic

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome'. Together they form a unique fingerprint.

Cite this